Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: ICUI stock price vs MCK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MCK's multiple
Needs MCK P/E.
Implied fair value · at ICUI's multiple
Needs ICUI P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ICUI FY 2025 (ended Dec 31, 2025) · MCK FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
ICU MEDICAL INC/DE · implied price per share
Bear
$60.42
Base
$71.09
Bull
$81.75
McKESSON CORPORATION · implied price per share
Bear
-$983.83
Base
-$1.16K
Bull
-$1.33K
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.60x
-2.99x
Net debt / EBITDA
Leverage against operating earnings
2.62x
0.36x
Cash and equivalents
Liquid reserves on the balance sheet
$223.47M
$3.98B
Total debt
Interest-bearing obligations outstanding
$1.28B
$6.50B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BECTON DICKINSON & CO
ICUI vs BDX
TELEFLEX INC
ICUI vs TFX
HAEMONETICS CORP
ICUI vs HAE
BAXTER INTERNATIONAL INC
ICUI vs BAX
CARDINAL HEALTH INC
ICUI vs CAH
AbbVie Inc.
ICUI vs ABBV
HENRY SCHEIN INC
ICUI vs HSIC
PATTERSON COMPANIES, INC.
ICUI vs PDCO
Zoetis Inc.
ICUI vs ZTS
CVS HEALTH Corp
ICUI vs CVS
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe ICUI can reaccelerate revenue growth and convert its strong gross margin into higher net earnings, then hold or accumulate because the stock already sits within its historical range and below the DCF band; otherwise, the valuation looks hard to justify versus MCK on current earnings and sales multiples.
ICUI's current price of $168.51 sits far above MCK-implied P/E price of $0.67, which implies a -99.6% downside under that framework. However, MCK comparison is distorted by ICUI's extremely high P/E of 5617.0x versus MCK's 22.3x, while ICUI trades at a richer P/S of 1.9x versus MCK's 0.3x.
Supporting Metrics
